Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap

Asthma–COPD overlap (ACO) is a type of incomplete obstructive airway disease that has a high incidence and mortality. Nevertheless, there is currently no clear definition of ACO and no effective intervention. The newly discovered phosphodiesterase-4 inhibitor, roflumilast, has shown initial efficacy...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Drug Des Devel Ther
Päätekijät: Zhang, Xiaoli, Chen, Yuqing, Fan, Liyu, Ye, Jiaqi, Fan, Junsheng, Xu, Xinjie, You, Danming, Liu, Sihan, Chen, Xin, Luo, Peng
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2018
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6078181/
https://ncbi.nlm.nih.gov/pubmed/30122895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S165161
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia